Insider · SEC Form 4 filer
Michael Hayden
Companies
Where they file as an insider
Ionis Pharmaceuticals (IONS) Director Latest filing Nov 10, 2026
AbCellera Biologics (ABCL) Director Latest filing Aug 24, 2026
89bio (ETNB) Director Latest filing Oct 30, 2025
Track record
Did their buys beat the typical stock?
Open-market buys8
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check3
Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.
Ionis Pharmaceuticals (IONS) Bought Nov 10, 2026 · $148K · 5,000 shares Too new Too new. Its 6-month check uses prices as of Jun 30, 2027.
AbCellera Biologics (ABCL) Bought Aug 12–24, 2026 · $1.05M · 100,000 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Ionis Pharmaceuticals (IONS) Bought Jul 30–31, 2026 · $1.06M · 20,000 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Ionis Pharmaceuticals (IONS) Bought May 1, 2025 · $478K · 15,000 shares Beat typical Jun 30, 2025 $39.51 → Dec 31, 2025 $79.11 · +100.2% (typical stock +2.1%)
Ionis Pharmaceuticals (IONS) Bought Dec 23, 2024 · $181K · 5,000 shares Beat typical Dec 31, 2024 $34.96 → Jun 30, 2025 $39.51 · +13.0% (typical stock −3.4%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.